• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stereotaxis nosedives on suspended guidance and harsh quarter

Stereotaxis nosedives on suspended guidance and harsh quarter

August 10, 2011 By MassDevice staff

Stereotaxis

Robotic cardiac surgical systems maker Stereotaxis, Inc. (NSDQ:STXS) watched its share price plunge hard and fast as it suspended 2011 guidance on a weak second quarter earnings report.

Shares sank 58 percent from Monday’s close of $2.85 to $1.19 at the end of the day yesterday, inching toward the company’s 52-week low of $1.11.

Sales for the three months ended June 30 dropped 23 percent to $11.6 million, compared to $15 million during the same period last year. Losses more than doubled for the quarter to $9.7 million, or a loss of 18 cents per share, compared with losses of $3.9 million, or 8 cents lost per share, in Q2 2010.

Citing "corporate developments and an uncertain business environment," St. Louis-based Stereotaxis withdrew its previous financial guidance and temporarily suspended providing guidance for this year "until there is more predictability to the company’s magnetic platform business."

"Our revenue and new capital order performance is being impacted by a slowdown in Niobe II momentum and the related impact on the Odyssey business due to delays of Odyssey installations in Niobe labs," president & CEO Michael Kaminski said in the report. "We are committed to taking the necessary actions to improve our operating performance, enhance our competitive position and strengthen the business for the long term."

Stereotaxis plans to reduce operating expenses by 15 to 20 percent to minimize cash burn while continuing to fund research and development. It is also exploring options to raise cash without hurting shareholder value. Stereotaxis expects its efforts to come through in Q4.

"We need to take difficult but prudent actions to significantly reduce our costs as the market awaits the availability of Epoch, and we are immediately implementing overhead cost-reduction initiatives that will significantly realign and reduce operating expenses and minimize cash burn, while maintaining R&D investments to fund high growth opportunities like the continued advancement of our robotic technology platform," Kaminski said.

STXS stock has managed to avoid sinking further today, with shares trading around $1.20 mid-morning.

Meanwhile, company CFO Dan Johnston resigned from his post, effective August 15, to pursue other professional interests. He will remain on as a consultant until the end of the year.

Filed Under: MassDevice Earnings Roundup, News Well, Surgical Robotics, Wall Street Beat Tagged With: Q2, Stereotaxis

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy